How much funding has Monte Rosa Therapeutics raised?

Monte Rosa Therapeutics has raised $127.5M in total funding, most recently a Series C round.

Who are Monte Rosa Therapeutics's investors?

Monte Rosa Therapeutics's investors include Avoro Ventures, NEA, Jerel Davis, GV.

When was Monte Rosa Therapeutics founded?

Monte Rosa Therapeutics was founded in 2018.

Where is Monte Rosa Therapeutics headquartered?

Monte Rosa Therapeutics is headquartered in Boston, Massachusetts, United States.

What industry is Monte Rosa Therapeutics in?

Monte Rosa Therapeutics operates in Biotech, Drug Discovery, Healthcare, Therapeutics.

How many employees does Monte Rosa Therapeutics have?

Monte Rosa Therapeutics has 51-200 employees.

Monte Rosa Therapeutics

IPO

Degrading proteins, making medicines

Public · Boston, United States · Founded 2018 · $127.5M raised

Headquarters: Boston, Massachusetts
Employees: 51–200
Founded: 2018
Business Model: B2B
Website: monterosatx.com

Total Funding: $127.5M
Last Round: $95.0M Series CMar 2021
Rounds: 2
Type: Public

About

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degrader (MGD) medicines that reprogram ubiquitin ligases to eliminate disease-driving proteins previously considered undruggable. The company's proprietary platform integrates MGD chemistry, AI, structural biology, and proteomics to advance programs targeting cancer and other serious diseases.

Summary

Monte Rosa Therapeutics is a Biotech company based in Boston, United States, founded in 2018. It has raised $127.5M in total across 2 rounds, most recently a $95.0M Series C round in Mar 2021. Investors include Avoro Ventures, NEA and Jerel Davis.

LinkedIn X (Twitter)